TAXIS Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:TAXIS Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10871
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
TAXIS Pharmaceuticals Inc (TAXIS Pharma) is a biopharmaceutical company that treats, reduce and eliminates the threat of current and emergent antimicrobial resistance across a range of infectious diseases. It research new classes of antibiotic agents to treat life-threatening and multidrug-resistant bacterial infections. TAXIS Pharma’s pipeline includes various investigational antibiotics with novel mechanisms of action including efflux pump inhibition (EPI), inhibition of the bacterial protein FtsZ, and modulation of another bacterial protein (MreB). The company offers services such as research and development, chemical synthesis and laboratory services. Its products are used in treatment of bacterial infections, and others. TAXIS Pharma is headquartered in Monmouth Junction, New Jersey, the US.

TAXIS Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
TAXIS Pharma Acquires Antimicrobial Drugs from Biota Pharma 10
Venture Financing 11
Taxis Pharma to Raise USD5 Million in Venture Financing 11
Taxis Pharma Raises USD1.2 Million in Venture Financing 12
Taxis Pharma Raises USD3 Million in Venture Financing 13
TAXIS Pharmaceuticals Inc – Key Competitors 14
TAXIS Pharmaceuticals Inc – Key Employees 15
TAXIS Pharmaceuticals Inc – Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
TAXIS Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
TAXIS Pharma Acquires Antimicrobial Drugs from Biota Pharma 10
Taxis Pharma to Raise USD5 Million in Venture Financing 11
Taxis Pharma Raises USD1.2 Million in Venture Financing 12
Taxis Pharma Raises USD3 Million in Venture Financing 13
TAXIS Pharmaceuticals Inc, Key Competitors 14
TAXIS Pharmaceuticals Inc, Key Employees 15

List of Figures
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
TAXIS Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[TAXIS Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Luye Pharma Group Ltd (2186):企業の財務・戦略的SWOT分析
    Summary Luye Pharma Group Ltd (Luye Pharma Group) is a drug company that manufactures, develops, discovers, and commercializes novel formulations, natural drugs, medicinal products, pharmaceutical products, and biotechnology products. The group’s products include paclitaxel liposome, lentinan, sodiu …
  • Evoqua Water Technologies Corp (AQUA):企業の財務・戦略的SWOT分析
    Evoqua Water Technologies Corp (AQUA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Intarcia Therapeutics Inc-医療機器分野:企業M&A・提携分析
    Summary Intarcia Therapeutics Inc (Intarcia), formerly BioMedicines Inc, is a biopharmaceutical company that discovers, develops and commercializes drug therapies to reduce effects for chronic diseases. The company’s product candidate include ITCA 650, which is in Phase III clinical trial. Its ITCA …
  • NIIT Technologies Ltd (NIITTECH):企業の財務・戦略的SWOT分析
    Summary NIIT Technologies Ltd (NIIT Technologies) is a technology company that provides information technology solutions. The company provides software products such as AdvantageSuite, an insurance technology solution based on Microsoft Azure cloud platform. It offers services such as application ma …
  • Pets at Home Group Plc (PETS):企業の財務・戦略的SWOT分析
    Pets at Home Group Plc (PETS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Senseonics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Senseonics Inc (Senseonics), a subsidiary of Senseonics Holdings Inc, is a medical device company that designs, develops and commercializes of glucose monitoring products. Its products, Eversense and Eversense XL, are implantable continuous glucose monitoring (CGM) systems that help people w …
  • SPIE Nucleaire:企業の戦略的SWOT分析
    SPIE Nucleaire - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • TimberWest Forest Corporation:企業の戦略・SWOT・財務情報
    TimberWest Forest Corporation - Strategy, SWOT and Corporate Finance Report Summary TimberWest Forest Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Relay Medical Corp (CHX):企業の財務・戦略的SWOT分析
    Summary Relay Medical Corp(Relay), formerly Chromedx Corp, is a medical technology company that develops medical devices for in vitro diagnostics and point-of-care testing. The company offers technologies based on granted and pending patents such as HemoPalm and AUF. Its HemoPalm provides a combinat …
  • CMIC Holdings Co Ltd (2309):製薬・医療:M&Aディール及び事業提携情報
    Summary CMIC Holdings Co Ltd (CMIC) is a contract research organization that supports drug development services. The organization offers medical research related services to pharmaceuticals and medical organizations. Its CRO business services include monitoring, data management, STAT analysis, regis …
  • PhoenixBio Co Ltd (6190):企業の財務・戦略的SWOT分析
    Summary PhoenixBio Co Ltd (PhoenixBio) is a life science company that offers medical therapy solutions. The company offers contract study services including dosing of test-compounds, sampling, in-life phase trials, chemical analysis, measurement of human albumin levels, and metabolic enzymes and blo …
  • IPCA Laboratories Ltd (IPCALAB):企業の財務・戦略的SWOT分析
    Summary IPCA Laboratories Ltd (IPCA) is a manufacturer and supplier of active pharmaceutical ingredients (API’s), generics and branded formulations. It is one of India's largest formulation exporters and is specialized in anti-malarial and anti-bacterials therapeutic segments. The company offers API …
  • ALS Ltd (ALQ):企業の財務・戦略的SWOT分析
    ALS Ltd (ALQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Shelby Energy Cooperative, Inc.:企業の戦略的SWOT分析
    Shelby Energy Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • LSB Industries Inc (LXU):企業の財務・戦略的SWOT分析
    LSB Industries Inc (LXU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tokyo Electron Ltd (8035):企業の財務・戦略的SWOT分析
    Tokyo Electron Ltd (8035) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • UniQure NV (QURE):製薬・医療:M&Aディール及び事業提携情報
    Summary UniQure NV (UniQure) develops and markets gene therapy products. The company develops adeno-associated virus based gene therapies using its gene technology platform. UniQure offers clinical and preclinical programs for lipoprotein lipase deficiency, hemophilia A and B, Huntington’s disease, …
  • Sun Resources NL (SUR):石油・ガス:M&Aディール及び事業提携情報
    Summary Sun Resources NL (Sun Resources) is an oil and gas exploration and development company. The company explores and develops crude oil and natural gas. Its services include exploration, production, and development of unconventional oil and gas resources. Its projects include Delta Oil Project, …
  • Morneau Shepell Inc.:企業の戦略・SWOT・財務分析
    Morneau Shepell Inc. - Strategy, SWOT and Corporate Finance Report Summary Morneau Shepell Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Sohar Aluminium LLC:企業の戦略・SWOT・財務情報
    Sohar Aluminium LLC - Strategy, SWOT and Corporate Finance Report Summary Sohar Aluminium LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆